Revolution Medicines Inc. (NASDAQ:RVMD), on Sunday, unveiled breakthrough data showing its experimental pancreatic cancer pill more than doubled median overall survival compared with chemotherapy in a pivotal study.
The Survival Benefit
Daraxonrasib reduced the risk of death by 60% versus chemotherapy and more than doubled median overall survival in previously treated patients with metastatic pancreatic cancer harboring KRAS mutations, the company said.
The study also met its progression-free survival endpoint, with patients on daraxonrasib experiencing substantially longer disease control than those receiving standard treatment.
“These results will change how scientists, clinicians, and patients think about treatment for pancreatic cancer,” Brian M. Wolpin, Harvard’s Dana-Farber Cancer Institute and principal investigator for the trial said, adding that the results establish a new standard of care for patients whose disease has already been treated.
